Skip to main content
Quest Diagnostics

US Patterns in Islet Autoantibody (iAb) Testing of Nondiabetic Individuals Before and After Publication and Approval of an Immunotherapy to Delay Stage 3 Type 1 Diabetes (T1D) Onset

IDS 2024

Immunology of Diabetes Society

Bruge, Belgium, Nov 4, 2024

Poster presentation: US Patterns in Islet Autoantibody (iAb) Testing of Nondiabetic Individuals Before and After Publication and Approval of an Immunotherapy to Delay Stage 3 Type 1 Diabetes (T1D) Onset.

Authors: Dixit S, Marcelli M, Chen Z, Bare L, Tong C, Sims E

Specialty: Cardiology, Endocrinology, Infectious disease

Related content

Test FAQ
Autoantibodies and Type 1 Diabetes (T1D)
Publication
Contributions of Glucose and Hemoglobin A1c Measurements in Diabetes Screening
On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.